Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • The Inquiry Report
    • Additional Compensation Report
    • First Interim Report
    • Second Interim Report
    • Compensation Framework Study
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • NHS Psychological Support
    • Confidential Psychological Support
    • Support Groups
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
  • Contact us
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Annual Returns for Birmingham Children's Hospital 1983 recorded an increase in Factorate usage with no indication of an increase in cryoprecipitate use

  • Read more about Annual Returns for Birmingham Children's Hospital 1983 recorded an increase in Factorate usage with no indication of an increase in cryoprecipitate use

Memo from Barry Barber to Brian Dyos regarding the visit report of Birmingham Children's Hospital in February 1981. Factorate usage was the mainstay of treatment that year. Cryoprecipitate primarily used to treat those with Von Willebrand's disease.

  • Read more about Memo from Barry Barber to Brian Dyos regarding the visit report of Birmingham Children's Hospital in February 1981. Factorate usage was the mainstay of treatment that year. Cryoprecipitate primarily used to treat those with Von Willebrand's disease.

Annual Returns for Birmingham Children's Hospital 1980 showed Factorate usage more than doubled from 1979.

  • Read more about Annual Returns for Birmingham Children's Hospital 1980 showed Factorate usage more than doubled from 1979.

Annual Returns for Birmingham Children's Hospital 1979 showed commercial concentrate usage in 1979 was almost double that of 1978.

  • Read more about Annual Returns for Birmingham Children's Hospital 1979 showed commercial concentrate usage in 1979 was almost double that of 1978.

Annual Returns for Birmingham Children's Hospital 1978 showed Factor 8 concentrate outstripped cryoprecipitate, with more commercial concentrate being used than NHS. The use of cryoprecipitate had reduced substantially from the previous year.

  • Read more about Annual Returns for Birmingham Children's Hospital 1978 showed Factor 8 concentrate outstripped cryoprecipitate, with more commercial concentrate being used than NHS. The use of cryoprecipitate had reduced substantially from the previous year.

In 1977 Birmingham Children's Hospital treated its Haemophilia A patients predominantly with cryoprecipitate together with some commercial concentrate. No NHS Factor 8 was used that year.

  • Read more about In 1977 Birmingham Children's Hospital treated its Haemophilia A patients predominantly with cryoprecipitate together with some commercial concentrate. No NHS Factor 8 was used that year.

The precise number of children infected with HIV as a consequence of their treatment at Alder Hey was unclear with a July 1987 report recording 16 cases.

  • Read more about The precise number of children infected with HIV as a consequence of their treatment at Alder Hey was unclear with a July 1987 report recording 16 cases.

A report from the solicitors representing the defendant health authority in the litigation recorded they were "unable" to show that cryoprecipitate and NHS Factor 8 concentrate were not available. Dr Martin "says that he gave no consideration to alternative treatment."

  • Read more about A report from the solicitors representing the defendant health authority in the litigation recorded they were "unable" to show that cryoprecipitate and NHS Factor 8 concentrate were not available. Dr Martin "says that he gave no consideration to alternative treatment."

A medical report on a child born in 1981, with moderate haemophilia, shows that he was treated with concentrates from the age of one and received treatment with concentrates on four occasions in 1983. The report from Dr Ludlam outlined that to justify the use of commercial factor VIII concentrate for this child it would have been necessary for Dr Martin to demonstrate several steps were taken to attempt to treat the child with cryoprecipitate

  • Read more about A medical report on a child born in 1981, with moderate haemophilia, shows that he was treated with concentrates from the age of one and received treatment with concentrates on four occasions in 1983. The report from Dr Ludlam outlined that to justify the use of commercial factor VIII concentrate for this child it would have been necessary for Dr Martin to demonstrate several steps were taken to attempt to treat the child with cryoprecipitate

Dr Martin did "not make it [his] practice to raise the hepatitis issue with families" and similarly, did not "wish to worry parents with what at first seemed to be a tenuous link" regarding AIDS.

  • Read more about Dr Martin did "not make it [his] practice to raise the hepatitis issue with families" and similarly, did not "wish to worry parents with what at first seemed to be a tenuous link" regarding AIDS.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Current page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.